JP2023531968A5 - - Google Patents

Info

Publication number
JP2023531968A5
JP2023531968A5 JP2022579724A JP2022579724A JP2023531968A5 JP 2023531968 A5 JP2023531968 A5 JP 2023531968A5 JP 2022579724 A JP2022579724 A JP 2022579724A JP 2022579724 A JP2022579724 A JP 2022579724A JP 2023531968 A5 JP2023531968 A5 JP 2023531968A5
Authority
JP
Japan
Application number
JP2022579724A
Other languages
Japanese (ja)
Other versions
JP2023531968A (ja
JPWO2022006305A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039945 external-priority patent/WO2022006305A1/en
Publication of JP2023531968A publication Critical patent/JP2023531968A/ja
Publication of JPWO2022006305A5 publication Critical patent/JPWO2022006305A5/ja
Publication of JP2023531968A5 publication Critical patent/JP2023531968A5/ja
Pending legal-status Critical Current

Links

JP2022579724A 2020-07-01 2021-06-30 抗bet v 1抗体を使用してアレルギーを治療する方法 Pending JP2023531968A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047126P 2020-07-01 2020-07-01
US63/047,126 2020-07-01
US202063129253P 2020-12-22 2020-12-22
US63/129,253 2020-12-22
PCT/US2021/039945 WO2022006305A1 (en) 2020-07-01 2021-06-30 Methods of treating allergy using anti-bet v 1 antibodies

Publications (3)

Publication Number Publication Date
JP2023531968A JP2023531968A (ja) 2023-07-26
JPWO2022006305A5 JPWO2022006305A5 (https=) 2024-07-08
JP2023531968A5 true JP2023531968A5 (https=) 2024-07-08

Family

ID=77168400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579724A Pending JP2023531968A (ja) 2020-07-01 2021-06-30 抗bet v 1抗体を使用してアレルギーを治療する方法

Country Status (12)

Country Link
US (2) US11897945B2 (https=)
EP (1) EP4175986A1 (https=)
JP (1) JP2023531968A (https=)
KR (1) KR20230030573A (https=)
CN (1) CN115698059A (https=)
AU (1) AU2021300129A1 (https=)
BR (1) BR112022026279A2 (https=)
CA (1) CA3177918A1 (https=)
CL (1) CL2022003744A1 (https=)
IL (1) IL299207A (https=)
MX (1) MX2022015677A (https=)
WO (1) WO2022006305A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298034B2 (en) * 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1219299T4 (da) 2000-12-28 2011-02-14 Biomay Ag Allergivacciner og fremstilling deraf
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Similar Documents

Publication Publication Date Title
CN305672679S (https=)
CN306020241S (https=)
CN305536121S (https=)
CN305534652S (https=)
CN305533108S (https=)
CN305532753S (https=)
CN305529634S (https=)
CN305527815S (https=)
CN305528617S (https=)
CN305528234S (https=)
CN305549414S (https=)
CN305561337S (https=)
CN305567222S (https=)
CN305527363S (https=)
CN306026428S (https=)
CN305822768S (https=)
CN306003458S (https=)
CN305980678S (https=)
CN305965535S (https=)
CN305637980S (https=)
CN305663616S (https=)
CN305665587S (https=)
CN305965149S (https=)
CN305667634S (https=)
CN305670537S (https=)